Option chain shows key data for Carmell's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Carmell.

Carmell (NASDAQ:CTCX) Stock, Option Chain

Carmell Therapeutics

Carmell Corp is a bio-aesthetics company that utilizes the Carmell Secretome to support skin and hair health. Its cosmetic skincare product portfolio includes Carmell G.L.E.E and various others in pipeline such as Youth restoring formula, Ultra-brightening formula, Ultra-hydrating formula, and Rapid Recovery formula among others. The company has one operating segment, principally the business of developing and commercializing bio-aesthetics and its bone and tissue healing products.

Redcliffe,,Queensland,,Australia,-,May,14,2018:,Domino's,Pizza,Store

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

AMAT

AREN

ASTS

BENF

CERO

CTCX

DBGI

DESP

GREE

JTAI

OKLO

QUBT

RCAT

SYTA

TCTM

TFFP

TIVC

XPON

Why Domino&#39;s Pizza Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

movers image

ATNF

BREA

CLMT

EFSH

GEVO

GRTS

KLTO

LCID

MTEM

PRQR

QNRX

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

AEHR

AKAN

AMLI

CETX

CMND

GLXG

KDLY

LILM

LKCO

LUXH

MLGO

MNTS

NIVF

TSLA

ZENA

Why Aehr Test Systems Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Carmell Corp

Amid growing scrutiny over <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">browser monopolies in the United States</a>, the United Kingdom&#8217;s&nbsp;Competition and Markets Authority (CMA)&nbsp;is considering launching an investigation into the mobile browser market, focusing on&nbsp;Apple Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and&nbsp;Google by Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). This potential probe could further challenge the duopoly&#8217;s grip on the market.
What Happened: The UK&#8217;s CMA has raised concerns about the current market dynamics, particularly regarding Apple&#8217;s policies, Reuters reported on Friday. The inquiry group has provisionally identified issues, suggesting that Apple&#8217;s rules may hinder innovation by restricting competitors from introducing new features on iPhones. Smaller British app developers reportedly face challenges in fully utilizing progressive web apps due to Apple&#8217;s device limitations, which offer an alternative to traditional app store downloads.
The report also pointed out a revenue-sharing agreement between Apple and Google, which allegedly reduces their motivation to compete in the mobile browser space on Apple devices. The CMA&#8217;s Digital Markets Unit, empowered to regulate big tech, is set to address these issues when its new regime begins in January.
See Also:&nbsp;<a href="https://www.benzinga.com/tech/24/11/42029736/elon-musk-says-ai-will-surpass-doctors-lawyers-after-chatgpt-tops-medical-diagnoses-humans-becoming-biological-backups?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Elon Musk Says AI Will Surpass Doctors, Lawyers After ChatGPT Tops Medical Diagnoses — Humans Becoming &#8216;B</a>
Apple&nbsp;has contested the CMA&#8217;s findings, arguing that the proposed interventions could compromise user privacy and security. The CMA plans&nbsp;to make a final decision&nbsp;on the matter by March, while no further action is expected on cloud gaming as previous concerns have been resolved.
Why It Matters: The potential investigation by the CMA comes at a time when&nbsp;Google&nbsp;is facing <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">significant antitrust scrutiny </a>in the United States. The U.S. Department of Justice has demanded that&nbsp;Alphabet Inc.&nbsp;divest its Chrome browser to dismantle its monopoly on online search. This move is part of broader efforts to restore competition in the search market.
Additionally, the antitrust ruling threatens&nbsp;Google&#8217;s<a href="https://www.benzinga.com/24/11/42083150/googles-20b-search-deal-with-apple-faces-collapse-after-antitrust-ruling-what-it-could-means-for-both-tech-giants">&nbsp;lucrative $20 billion agreement </a>with Apple, which makes its search engine the default on iPhones. This agreement has been crucial to Apple&#8217;s financial performance, highlighting the intertwined interests of these tech giants.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/42119020/alphabet-bleeds-over-120-billion-in-market-value-eyes-worst-day-in-10-months-after-doj-demands-google-chrome-sale?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Alphabet Bleeds Over $120 Billion In Market Value, Eyes Worst Day In 10 Months After DOJ Demands Google Chrome Sale</a></li>
</ul>
Photo Courtesy: Koshiro K On Shutterstock

Global

Tech

General

AAPL

GOOG

GOOGL

Amid Ongoing Browser Antitrust Scrutiny In US, UK Might Be Next To Challenge Apple And Google's Duopoly

Wells Fargo analyst Joe Quatrochi initiates coverage on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) with a Equal-Weight rating and announces Price Target of $215.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On Texas Instruments with Equal-Weight Rating, Announces Price Target of $215

XTKG

Trading Halt: Halt status updated at 8:55:00 AM ET: Quotation Resumption: News and Resumption Times

Decibel Cannabis Company Inc. (TSXV:<a class="ticker" href="https://www.benzinga.com/stock/DB#TSXV">DB</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/DBCCF#OTCQB">DBCCF</a>) announced its unaudited interim financial results on Thursday for the third quarter ending Sept. 30, 2024.
&#8220;Decibel has been very deliberate about reducing our current liabilities, by ~5mm this quarter," CEO Benjamin Sze said.&nbsp;"Maintaining discipline over time will result in a stronger balance sheet.&nbsp; This marks the last quarter where our primary focus is on Canadian domestic recreational sales. While we continue to integrate AgMedica into our portfolio, it is encouraging to see significant demand internationally for Decibel flower.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/08/40369534/decibel-cannabis-reports-22-yoy-decrease-in-q2-net-revenue-plans-to-benefit-with-new-product-lau">Decibel Cannabis Reports 22% YoY Decrease In Q2 Net Revenue, Plans To Benefit With New Product Launches</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q3 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$24.1 million ($17.2 million), representing a 9% increase sequentially, but a 12% decrease year-over-year.</li>
<li>Gross profit before fair value adjustments was CA$12.7 million, compared to roughly CA$12 million in the prior year's period.</li>
<li>Gross margin before fair value adjustments reached 53% in the third quarter, up from 44% in the prior year's period, reflecting improved operational efficiency.</li>
<li>Adjusted EBITDA was positive at CA$5.1 million, representing a 31% increase from the previous quarter but a 21% decrease year over year.</li>
<li>Net loss and comprehensive loss amounted to CA$585 000, compared to a net income and comprehensive income of CA$413 000.</li>
<li>Generated positive free cash flow of $1.8 million, up 75% year-over-year.</li>
</ul>
The company said that it's seeing significant demand for its flower internationally as it continues to integrate AgMedica.
Decibel <a href="https://www.benzinga.com/markets/cannabis/24/10/41600492/decibel-acquires-agmedica-announces-private-placement-and-third-quarter-guidance">closed the acquisition</a> of AgMedica Bioscience Ltd. in October. The transaction was arranged through an agreement with Callisto Capital Corp. and was made in exchange for a $6.3 million unsecured convertible debenture.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40577591/decibels-10m-strategy-how-it-could-enhance-your-canadian-cannabis-portfolio">Decibel&#8217;s $10M Strategy: How It Could Enhance Your Canadian Cannabis Portfolio</a></li>
</ul>
<h3 class="wp-block-heading">DBCCF Price Action</h3>
Decibel's shares traded 5.54% higher at $0.0495 per share after the market close on Thursday afternoon.

Cannabis

Earnings

DBCCF

TSXV:DB

Canadian Cannabis Co. Decibel Reports 12% YoY Drop In Q3 Revenue But Increases Gross Margin To 53%

Wells Fargo analyst Joe Quatrochi initiates coverage on Cadence Design Sys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NASDAQ">CDNS</a>) with a Overweight rating and announces Price Target of $350.

CDNS

Wells Fargo Initiates Coverage On Cadence Design Sys with Overweight Rating, Announces Price Target of $350

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee56ee7bf6000154d12e/tom-nikic">Needham analyst Tom Nikic</a> initiated coverage on NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) with a Buy rating and announced a price target of $84. Nike shares closed at $75.10 on Thursday. See how other analysts view this stock.</li>
<li>JP Morgan analyst Bennett Moore initiated coverage on Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) with an Overweight rating and announced a price target of $220. Carpenter Tech shares closed at $180.71 on Thursday. <a href="https://www.benzinga.com/quote/CRS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>B of A Securities analyst Tyler DuPont initiated coverage on Kyndryl Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KD#NYSE">KD</a>) with a Buy rating and announced a price target of $40. Kyndryl shares closed at $32.49 on Thursday. <a href="https://www.benzinga.com/quote/KD/analyst-ratings">See how other analysts view this stock.</a></li>
<li>UBS analyst John Hodulik initiated coverage on Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) with a Neutral rating and announced a price target of $73. Roku shares closed at $68.68 on Thursday. <a href="https://www.benzinga.com/quote/ROKU/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wells Fargo analyst Joe Quatrochi initiated coverage on Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) with an Overweight rating and announced a price target of $155. ARM shares closed at $133.14 on Thursday. <a href="https://www.benzinga.com/quote/ARM/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="544" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-1024x544.png" alt="" class="wp-image-660970" style="width:666px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-1024x544.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246-768x408.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22085052/image-246.png 1255w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

ROKU

This Nike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

HUDA

Hudson Acquisition I Corp Signs Definitive Business Combination Agreement With Aiways Europe; Transaction Represents Pre-Combination Equity Valuation Of $410M For Airways Europe, Subject To Adjustment

Wells Fargo analyst Joe Quatrochi initiates coverage on MaxLinear (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) with a Equal-Weight rating and announces Price Target of $14.

Wells Fargo Initiates Coverage On MaxLinear with Equal-Weight Rating, Announces Price Target of $14

Wells Fargo analyst Gary Mobley initiates coverage on Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Equal-Weight rating and announces Price Target of $220.

Wells Fargo Initiates Coverage On Analog Devices with Equal-Weight Rating, Announces Price Target of $220

The looming threat of the removal of the clean energy <a href="https://www.benzinga.com/news/24/09/40752747/trump-wants-to-end-ev-tax-credits-but-yellen-warns-of-higher-bills-lost-jobs-and-chinas-gain">tax credit has rattled some</a>, but JPMorgan analyst Bill Peterson says EVgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) is set up for success.
"EVGO sees improving affordability of a larger variety of vehicles as being the primary driver of mass EV adoption," Peterson says, adding, "new EV sales would need to decline by 40% to impact the company's trajectory, which is unlikely to happen."
Even if the credit is removed, Peterson forecasts that "16% US [battery electric vehicle] penetration by 2030" is still achievable.
Read Also: <a href="https://www.benzinga.com/news/earnings/24/11/41899963/evgo-q3-sales-surge-92-as-charging-revenues-and-customer-growth-drive-performance-stock-jumps">EVgo Q3 Sales Surge 92% As Charging Revenues And Customer Growth Drive Performance; Stock Jumps</a>
"While it has been reported that Trump's transition team intends to remove the 30D tax credit, there could be alternative ways that the administration changes it," he said, suggesting modifications like domestic content requirements or changes to MSRP and income eligibility.
<h2 class="wp-block-heading">EVgo&#8217;s Strategic Footprint Protects Growth</h2>
EVgo's strategic positioning in Republican-led states like Texas, Florida, and Arizona also sets it up for success, especially considering that these regions don't have the same emissions standards as California. Peterson added, "EVGO is relatively shielded from new EV sales growth, given it continues to drive momentum from a stable/growing EV fleet," while pointing to opportunities in autonomous and rideshare markets as potential additional growth drivers.
EVgo's confidence surrounding its Department of Energy (DOE) loan is "reaffirmed.&#8221; CEO Badar Khan called the process "de-risked" and nearing closure. Peterson feels the loan will allow EVgo to revise its EBITDA targets upward, stating, "We feel confident that EVGO will revise its EBITDA targets higher upon receiving the loan and disclose its planned build schedule through 2030."
<h2 class="wp-block-heading">Funding Concerns Seem Overblown</h2>
Despite some investor concerns about a potential clawback of funds, Peterson remains unconcerned, stating, "The government is unlikely to renegotiate its finalized contracts with US companies, especially if building charging infrastructure stimulates further EV demand and improves US competitiveness with China." 
Peterson also noted that, despite concerns over the loss of the 30C tax credit, "EVGO's business model is not reliant on highway sites."
<h2 class="wp-block-heading">EVGO Stock: A Bullish Trajectory</h2>
With 10,000 viable sites and further expansion on the horizon, EVgo's trajectory is still bullish. Peterson concluded that, "The opportunities for growth continue to increase with EV adoption," making EVgo a strong contender in the EV infrastructure race.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/11/41926301/sustainable-investment-under-trump-performance-matters-far-more-than-politics-jpmorgan-analyst-says">Sustainable Investment Under Trump: &#8216;Performance Matters Far More Than Politics,&#8217; JPMorgan Analyst Says</a></li>
</ul>

Analyst Color

Long Ideas

EVGO

EVgo Powers On Despite Trump Shake-Up: Analyst Projects 16% US Battery EV Penetration By 2030

Wells Fargo analyst Joe Quatrochi initiates coverage on NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Overweight rating and announces Price Target of $250.

NXPI

Wells Fargo Initiates Coverage On NXP Semiconductors with Overweight Rating, Announces Price Target of $250

WIIM

VRPX

Virpax shares are trading higher after the company announced results from the swine model dose range finding study for Probudur.

Evotec shares are trading lower after Halozyme withdrew its €2 billion proposal to acquire the company.

Jet.AI shares are trading higher after the company announced a fleet purchase agreement with Textron Aviation to purchase three Cessna Citation CJ3 Gen2 aircraft.

After Warren Buffett's conglomerate Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) declared its <a href="https://www.berkshirehathaway.com/qtrly/3rdqtr24.pdf">third-quarter results</a> in early November, investors have been curious as to why he sitting on nearly $325 billion in cash and equivalents.
What Happened: Analysts have been speculating an array of reasons for the world's most famous value investor to be holding such a huge pile of cash. It could be for an acquisition plan, a buyback<a href="https://www.benzinga.com/markets/24/11/41869558/warren-buffetts-apple-stake-reduction-spurs-97b-cash-surge-analysts-speculate-this-could-be-the-reas?utm_campaign=partner_feed&amp;utm_source=yahooFinance&amp;utm_medium=partner_feed&amp;utm_content=real_estate"> plan in case of a succession,</a> or an expectation of a market fall.
Also read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084722/warren-buffett-destroy[%E2%80%A6]-not-investing-in-bitcoin-says-microstrategys-michael-saylor">Warren Buffett &#8216;Destroying $3B A Month&#8217; Of Berkshire Capital By Not Investing In Bitcoin, Says MicroStrategy&#8217;s Michael Saylor</a>
The stock markets have been trading higher than their pre-election levels with a looming threat of a possible pause in the interest rate cuts. This has led analysts to wonder if Berkshire is avoiding investing because he cannot find any value in the markets at the current level.
&#8220;What some describe as a hot stock market, Warren Buffett would describe as overpriced,&#8221; Cathy Seifert, a director at CFRA Research <a href="https://fortune.com/2024/11/22/warren-buffett-berkshire-pool-dominos-nvidia-sidelines-hot-stock-market/">told</a> Fortune. 
Buffet&#8217;s current stance on the cash "reflects a fundamental skepticism about the sustainability of current market valuations, the sustainability of the Trump trade, combined with the fact that they're not seeing a lot of acquisition targets that are appealing to them,&#8221; she said.
The 94-year-old Buffet will be succeeded by Greg Abel to run Berkshire. "The unfortunate actuarial reality is, at some point in time, you have a change in senior management, and I suspect that they want to have a lot of cash to buy back Berkshire Hathaway stock," said Meyer Shields, managing director at Keefe, Bruyette &amp; Woods to <a href="https://fortune.com/2024/11/22/warren-buffett-berkshire-pool-dominos-nvidia-sidelines-hot-stock-market/">Fortune</a>. He implied that freely available cash can be utilized in case of a sell-off to benefit the shareholders
On the other hand, MicroStrategy Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) co-founder, Michael Saylor has said that <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42084722/warren-buffett-destroy[%E2%80%A6]-not-investing-in-bitcoin-says-microstrategys-michael-saylor">Buffett is destroying billions of dollars</a> in capital by not utilizing the cash at their disposal to invest in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>).
"That $320 billion.. that is destroying $32 billion a year. They are destroying $3 billion a month in capital because they're generating a 3% after-tax yield at best, and the cost of capital is 15%. So take 12% negative real yield," Saylor said.
Also read: <a href="https://www.benzinga.com/24/11/42132644/reddit-falls-7-in-afterhours-as-advance-plans-stake-sale-technicals-show-strong-support-but-selling-pressure-persists-at-overbought-levels">Reddit Tumbles 7% In Premarket Amid Advance&#8217;s Stake Sale Announcement: Technicals Show Strong Support, But Selling Pressure Persists At Overbought Levels</a>
Why It Matters: By holding cash and equivalents Berkshire could be making only &#8220;3% after-tax yield at best, and the cost of capital is 15%. So take 12% negative real yield,&#8221; said MicroStrategy&#8217;s Saylor
While analysts speculate various reasons, Saylor in a podcast with Patrick Bet-David made a case for Buffet to invest in Bitcoin. "I'd want to bet you that if I had an hour alone with Buffett in a calm environment, I'd walk out and he would say this Bitcoin thing is a pretty good idea."
Saylor was optimistic that Buffett would have wanted to buy Bitcoin after the interaction and would come out saying that the late Charlie Munger would have liked the idea.
Read next: <a href="https://www.benzinga.com/24/11/42134031/markets-got-it-wrong-after-elections-prospects-of-tariffs-not-good-for-equities-vs-dollar-says-ex-goldman-sachs-analyst">Markets Misread Trump Win, Says Ex-Goldman Sachs Analyst: &#8216;Prospects Of Tariffs Not Good For Equities&#8217;</a>
Image via Shutterstock

Equities

$BTC

MSTR

As MSTR's Michael Saylor Says Warren Buffett Is 'Destroying' Berkshire Capital, Analyst Suggests 'Overpriced…Hot Stock Market' Could Be The Reason Oracle Of Omaha Is Sitting On $325B Cash

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d223/deane-dray">RBC Capital analyst Deane Dray</a> upgraded the rating for Flowserve Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLS#NYSE">FLS</a>) from Sector Perform to Outperform and announced a $69 price target. Flowserve shares closed at $60.05 on Thursday. See how other analysts view this stock.</li>
<li>Keybanc analyst Jeffrey Hammond upgraded RBC Bearings Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBC#NYSE">RBC</a>) from Sector Weight to Overweight and announced a $375 price target. RBC Bearings shares closed at $324.45 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird analyst Shrenik Kothari upgraded the rating for Elastic N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) from Neutral to Outperform and raised the price target from $95 to $135. Elastic shares closed at $94.13 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners analyst David Risinger upgraded the rating for AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) from Market Perform to Outperform and announced a $206 price target. AbbVie shares closed at $171.73 on Thursday. <a href="https://www.benzinga.com/quote/PNW/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Seaport Global analyst Glenn Chin upgraded Sonic Automotive, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAH#NYSE">SAH</a>) from Neutral to Buy and announced a $74 price target. Sonic Automotive shares closed at $63.20 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying ESTC stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="559" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png" alt="" class="wp-image-660959" style="width:657px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-1024x559.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-300x164.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245-768x419.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/22084048/image-245.png 1205w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:<a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november"> </a>
<ul>
<li><a href="https://www.benzinga.com/24/11/42135346/top-3-materials-stocks-that-could-blast-off-in-november">Top 3 Materials Stocks That Could Blast Off In November</a></li>
</ul>

Upgrades

ABBV

ESTC

This Elastic Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Beneficient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BENF#NASDAQ">BENF</a>) shares are trading higher premarket on Friday after the company disclosed that its subsidiary, Beneficient Company Holdings, L.P., has completed a transaction where approximately $35 million of its preferred equity was redesignated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42133708/beneficient-consummates-transaction-to-increase-permanent-equity-by-35-million" rel="noreferrer noopener">as non-redeemable</a>.
This transaction resulted in the addition of approximately $35 million in permanent equity to the balance sheet.
Consequently, the company now believes it meets the Nasdaq Minimum Stockholders&#8217; Equity Requirement, with stockholders&#8217; equity of at least $2.5 million. However, Nasdaq&#8217;s final determination will confirm the company&#8217;s compliance.
Beneficient also announced the appointment of Karen J. Wendel as an independent member of its Board of <a target="_blank" href="https://www.benzinga.com//node/42133707" rel="noreferrer noopener">Directors as of November 21.</a>
Apart from this, Beneficient, through its subsidiary Beneficient Fiduciary Financial, L.L.C., provided an update to the State of Kansas Joint Committee on<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42126842/beneficient-reports-to-kansas-legislative-committee-on-its-positive-developments-and-the-digital-t" rel="noreferrer noopener"> Fiduciary Financial Institutions Oversight</a>.
The update highlighted the company&#8217;s business operations, digital innovations in the alternative asset industry, and its contributions to economic development in Kansas communities.
During its testimony, Beneficient executives reviewed the company&#8217;s fiscal second-quarter results for the period ending September 30, 2024, marking the second consecutive quarter of positive diluted earnings per share for its common shareholders.
The company highlighted advancements in its financial industry-focused business, including new technology innovations, an authorization from its board to complete up to $5 billion in fiduciary financings, and a transaction that reclassified certain preferred equity, increasing Beneficient&#8217;s permanent equity by $126 million.
The testimony also emphasized progress on key projects funded primarily by proceeds generated under the Kansas Technology-Enabled Fiduciary Financial Institutions (TEFFI) Act.
Price Action: BENF shares are up 18.2% at $1.04 premarket at the last check Friday.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42134782" target="_blank" rel="noreferrer noopener">After Plunging 16%, MicroStrategy Makes Modest Recovery In Friday Pre-Market: Is There Still Hope For A $100K BTC Effect?</a></li>
</ul>

Large Cap

Legal

Beneficient Adds $35 Million In Permanent Equity, Aiming For Nasdaq Compliance

BTAI

BioXcel Therapeutics shares are trading lower after the company announced a public offering valued at $7 million consisting of shares and warrants.

Offerings

INDP

Indaptus Therapeutics Announces $2.135M Registered Direct Offering And Private Placement, Issuing Shares And Warrants At $1.175 Per Unit, With Closing Expected November 25, 2024

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment

Biotech

APVO

Aptevo Provided Details About Portfolio On Cancer Immunotherapy

Carmell CEO buys shares worth over $15.5k - filing

Carmell looks to sell Axolotl Biologix

Carmell Corporation files to sell 1.33M for holders

Carmell Corporation files to sell 1.33M shares for holders

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the first quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q1-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q1 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the fourth quarter of 2023.<ul><li>Carmell Therapeutics reported earnings per share of $1.35.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ctcx-stock-earnings-carmell-therapeutics-for-q4-of-2023/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q4 2023

Carmell appoints Kendra Bracken-Ferguson as CEO

An update from Carmell Therapeutics (CTCX) is now available. Carmell Corporation has announced a major leadership change with Rajiv S. Shukla stepp...

Carmell Therapeutics Announces CEO Transition and New Leadership Incentives

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Carmell Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ctcx-stock-quote/">CTCX</a>) just reported results for the second quarter of 2024.<ul><li>Carmell Therapeutics reported earnings per share of -16 cents.</li><li>The company reported revenue of $12,320.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ctcx-stock-earnings-carmell-therapeutics-for-q2-of-2024/">CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CTCX Stock Earnings: Carmell Therapeutics Reported Results for Q2 2024

Carmell Therapeutics ( ($CTCX) ) has shared an announcement. Carmell Corporation is making waves in the skincare industry with its revolutionary Ca...

Carmell Therapeutics Unveils Innovative Skincare Breakthroughs

Press Releases

Carmell Announces Product Development Completed for G.L.E.E. Launch in March 2024

Health Care

Carmell to Host Investor Webinar, "Unveiling the Secretome: On the Eve of Product Launch" Featuring Key Opinion Leaders in the Medical Aesthetics Field

Contracts

Carmell Sharpens Aesthetics Focus with Execution of Definitive Agreement to Sell Axolotl Biologix Subsidiary

Carmell Announces Successful Closing of Axolotl Biologix Sale Transaction

Financing

Carmell Announces $3.0 Million Private Placement

Carmell Announces Successful Closing of $3.0 Million Private Placement

Management

Carmell Corporation Appoints New CEO Following Addition to the Russell Microcap Index

Carmell Corporation Launches Skincare Partnership With Ladies Playbook to Support and Celebrate NFL Sports Community

Comments

Carmell

Carmell (CTCX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga